Treg Therapy · Immune System · Treatment
The phrase "immune reset" gets used loosely in wellness circles — often attached to supplements, diets, or protocols that have little to do with actual immune biology. When we use it at the Lyme Immunotherapy Center, we mean something specific and mechanistic: the restoration of T-Regulatory cell function to a state capable of governing immune responses appropriately.
This is not a metaphor. It is a cellular intervention with a defined mechanism, a measurable target, and decades of immunological research behind it. Understanding what actually resets — and why it matters so profoundly for chronic Lyme patients — is the foundation for understanding why this approach works when so many others don't.
Chronic Lyme disease is not simply an ongoing infection. It is, at its core, an immune system that has lost its regulatory architecture. The infection may have triggered the initial dysfunction, but what perpetuates the suffering is an immune response that has become self-sustaining, disproportionate, and incapable of returning to a regulated baseline on its own.
In a healthy immune system, T-Regulatory cells — Tregs — act as the governing mechanism. They release calming cytokines, absorb the pro-inflammatory signals that drive immune overactivation, and physically disable the surface molecules that trigger immune attacks. When this population functions normally, the immune system responds to threats with precision and stops when the threat is resolved.
In chronic Lyme patients, this mechanism has failed. Not disappeared — failed. The Tregs are present but dysfunctional, their governing gene FOXP3 destabilized by the sustained inflammatory environment, leaving the immune system without meaningful regulatory control.
Autologous Treg therapy does not introduce foreign cells, suppress the immune system broadly, or rely on drugs to manage symptoms. It uses the patient's own T cells, engineers them to carry a stabilized version of the FOXP3 gene, and reintroduces them into the body where they begin performing the regulatory function that the patient's native Tregs have lost.
The word "reset" is earned here because what changes is not just the level of inflammation — it is the immune system's capacity to regulate itself. This is a fundamentally different intervention than anti-inflammatory medication, which manages the downstream symptom. Treg therapy addresses the upstream cause.
T cells are drawn from the patient and those with the appropriate regulatory profile are isolated. Because the cells are autologous — from the patient — there is no rejection risk and no foreign tissue.
The selected cells receive a stabilized FOXP3 construct — engineered to remain active even in the chronic inflammatory environment that destabilized the patient's native regulatory cells. Without this step, reinfused cells would fail for the same reasons the original Tregs did.
Before expansion, cells are placed in a laboratory environment replicating the patient's own inflammatory conditions. Only cells that maintain regulatory function under that pressure are selected to continue. This is not theoretical — it is empirical proof of resilience.
Validated cells are expanded by millions and reinfused intravenously. They travel to sites of active inflammation throughout the body and begin restoring the regulatory signals that chronic Lyme has silenced.
The immune changes that follow successful Treg therapy are not vague or nonspecific. They occur through defined pathways that have been studied extensively in immunological research.
IL-10 and TGF-beta production increases. These are the primary calming cytokines that functional Tregs release. As reinfused cells establish regulatory control, levels of these anti-inflammatory signals rise — directly counteracting the pro-inflammatory cytokine burden that drives Lyme symptoms.
IL-2 absorption increases. Activated Tregs carry the high-affinity CD25 receptor, which absorbs IL-2 — the fuel that aggressive immune cells depend on to sustain their attack. By consuming this signal, Tregs effectively starve the immune overactivation driving chronic inflammation.
Antigen-presenting cell activation decreases. Through a process called transendocytosis, Tregs physically strip the activation molecules off the surface of antigen-presenting cells — removing the "go" signal that keeps triggering immune responses. This is one of the most direct mechanisms by which Treg therapy interrupts the self-perpetuating cycle of chronic immune activation.
This distinction matters enormously, particularly for patients who have been harmed by immunosuppressive drugs or who are concerned about compromising their ability to fight infection.
Treg therapy is not immunosuppression. Immunosuppressive drugs — corticosteroids, methotrexate, biologics — work by broadly dampening immune function. They reduce inflammation, but they do so by making the entire immune system less capable. The consequence is increased infection risk, impaired healing, and a return of symptoms the moment the drug is withdrawn.
Treg therapy restores regulation, not suppression. A properly regulated immune system is not a weaker immune system. It is a more precise one — capable of mounting strong responses to genuine threats and stopping when those threats are resolved. Patients who have undergone Treg therapy do not become immunocompromised. They become immunoregulated — which is what a healthy immune system actually is.
The core distinction: Immunosuppression turns down the volume on the entire immune system. Treg therapy restores the conductor — so the orchestra can play the right notes at the right time, and stop when the piece is finished.
The chronic Lyme immune environment is uniquely hostile to conventional approaches. Anti-inflammatory treatments reduce symptoms temporarily but don't address the regulatory failure. Antimicrobials target the pathogen but don't restore immune architecture. Immune stimulants can worsen an already overactivated system.
Treg therapy is the only intervention that directly targets the regulatory mechanism at the center of the dysfunction. It doesn't ask the immune system to fight harder or calm down — it gives it back the tools to regulate itself. That distinction is what makes it a genuine reset, and why patients who have exhausted other options continue to find meaningful recovery through this approach.
Our team evaluates every patient individually. If immune dysregulation is driving your symptoms, we can assess whether autologous Treg therapy is the right next step.
Check My Eligibility